Over the past few years, a new class of injectable medications has changed the way obesity is treated. Two drugs—tirzepatide and semaglutide—have shown striking results in helping people lose weight ...

Zealand Pharma A/S' obesity drug pipeline, including petrelintide, shows promise but faces high risks. Click to explore ZLDPF ...

Jørgensen will step down after eight years as CEO, with a successor search underway while the company reaffirms confidence in ...

muscle volume z-score and muscle fat infiltration in people with type 2 diabetes (T2D) A recent post-hoc analysis of Lilly’s SURPASS-3 trial unravels the impact of tirzepatide treatment on ...

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...

A global trial reveals tirzepatide helps people lose more weight faster than semaglutide. This breakthrough could change ...

New animal research being presented at this year's European Congress on Obesity (ECO) in Malaga, Spain (11-14 May), reveals ...

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in ...

Viking's leading drug candidate could be a blockbuster in the weight loss market, which experts believe could grow to $150 billion over the coming years.

It is estimated that by 2030 the prevalence of MASH (Metabolic Dysfunction-Associated Steatohepatitis) in the Canadian general population will increase from 5.2% to 6.5%. 1 Left untreated, MASH can ...

Novo Nordisk's semaglutide is the active compound in Ozempic and Wegovy, while Lilly's tirzepatide is the active drug in Mounjaro and Zepbound.

“Building on encouraging data from the phase 2 study, our current trial shows improvement in two areas of disease activity: steatohepatitis and fibrosis stage,” the study authors wrote. “On the basis ...